CLAIMS

1. A compound according to Formula I



(I)

or a pharmaceutically acceptable salt and/or solvate thereof, wherein

R^1, R^2, and R^3 are each independently H, C_1-C_3 alkyl, C_1-C_3 alkoxy, trifluoromethyl, trifluoromethoxy, trialkyl ammonium, pentafluorosulfanyl, halo, or -N(R^{10})(R^{11});

R^4, R^5, R^6, and R^7 are each independently H, C_1-C_3 alkyl, C_1-C_3 alkoxy, trifluoromethyl, trifluoromethoxy, trialkyl ammonium, pentafluorosulfanyl, halo, or -N(R^{12})(R^{13});

R^8 is aryl or heteroaryl;

R^9 is H, C_1-C_3 alkyl, or fluoro; and

R^{10}, R^{11}, R^{12}, and R^{13} are each independently C_1-C_3 alkyl.

2. The compound of claim 1, wherein R^1, R^2, and R^3 are each independently H, C_1-C_3 alkyl, C_1-C_3 alkoxy, trifluoromethyl, trifluoromethoxy, halo, or -N(R^{10})(R^{11}).

3. The compound of claim 1, wherein R^1, R^2, and R^3 are each independently H, C_1-C_3 alkyl, C_1-C_3 alkoxy, halo, or -N(Me)$_2$.

4. The compound of claim 1, wherein R^1, R^2, and R^3 are each independently H, methyl, methoxy, isopropyl, isopropoxy, fluoro, or -N(Me)$_2$.

5. The compound of claim 1, wherein R^3 is methoxy.

6. The compound of claim 1, wherein R^4, R^5, R^6, and R^7 are each independently H, C_1-C_3 alkyl, C_1-C_3 alkoxy, trifluoromethyl, trifluoromethoxy, halo, or -N(R^{12})(R^{13}).

7. The compound of claim 1, wherein R^4, R^5, R^6, and R^7 are each independently H, C_1-C_3 alkyl, C_1-C_3 alkoxy, halo, or -N(Me)$_2$.

8. The compound of claim 1, wherein R^4, R^5, R^6, and R^7 are each independently H, methyl, methoxy, isopropyl, isopropoxy, fluoro, or -N(Me)$_2$.

9. The compound of claim 1, wherein R^6 is isopropoxy.

10. The compound of claim 1, where the compound is of Formula IA



(IA)

or a pharmaceutically acceptable salt and/or solvate thereof.

11. The compound of claim 1, wherein the compound is of Formula IB



(IA)

or a pharmaceutically acceptable salt and/or solvate thereof, wherein

R^{14}, R^{15}, and R^{16} are each independently H, C_1-C_3 alkyl, C_1-C_3 alkoxy, trifluoromethyl, trifluoromethoxy, trialkyl ammonium, pentafluorosulfanyl, halo, aryloxy, aryloyl, hydroxyl, amino, or amido.

12. The compound of claim 11, wherein R^{14}, R^{15}, and R^{16} are each independently H, C_1-C_3 alkyl, C_1-C_3 alkoxy, trifluoromethyl, trifluoromethoxy, halo, aryloxy, aryloyl, or -$N(C_1$-C_3 alkyl$)_2$.

13. The compound of claim 11, wherein R^{14}, R^{15}, and R^{16} are each independently H, C_1-C_3 alkyl, C_1-C_3 alkoxy, trifluoromethyl, trifluoromethoxy, halo, or -$N(Me)_2$.

14. The compound of claim 11, wherein R^{14}, R^{15}, and R^{16} are each independently H, methyl, methoxy, isopropyl, isopropoxy, fluoro, or -$N(Me)_2$.

15. The compound of claim 11, wherein R^{14}, R^{15}, and R^{16} are each independently H.

16. The compound of claim 1, wherein the compound is



,



,



,



,



,



,


F
H
N
O
O
Me
,


F
H
N
Cl
N
Me
Me
,


F
H
N
F
O
,



,



,



,



,

or a pharmaceutically acceptable salt and/or solvate thereof.

17. The compound of claim 1, wherein the compound is of Formula IC



(IC)

or a pharmaceutically acceptable salt and/or solvate thereof.

18. The compound of claim 1, wherein the compound is



,



,



,



,



,



,


F
H
N
O
O
Me
,


F
H
N
Cl
N
Me
Me
,


F
H
N
F
O
,



,



,



,



,

or a pharmaceutically acceptable salt and/or solvate thereof.

19. A composition comprising

a compound of any one of claims 1-18; and

a pharmaceutically acceptable carrier.

20. A pharmaceutical composition comprising

an effective amount of a compound of any one of claims 1-18 for treating pathogenic cellular proliferation, angiogenesis, cancer, metastatic disease, and/or a pathogenic vascular proliferative disease in a subject; and

a pharmaceutically acceptable carrier.

21. The pharmaceutical composition of claim 20, wherein the pathogenic vascular proliferative disease comprises pathogenic neovascularization associated with a cancer disease or condition.

22. The pharmaceutical composition of claim 20, wherein the pathogenic vascular proliferative disease comprises an ocular disease.

23. The pharmaceutical composition of claim 22,wherein the ocular disease is selected from the group consisting of age-related macular degeneration (AMD), diabetic retinopathy, retinopathy of prematurity, sickle cell retinopathy, retinal venous occlusive disease, central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), neovascular macular degeneration or an ocular cancer.

24. The pharmaceutical composition of claim 20, wherein the pathogenic vascular proliferative disease comprises age-related macular degeneration (AMD).

25. The pharmaceutical composition of claim 20, wherein the pathogenic vascular proliferative disease comprises wet, exudative age-related macular degeneration.

26. The pharmaceutical composition of claim 20, wherein the cancer comprises cholangiocarcinoma, triple negative breast cancer, or colorectal cancer.

27. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition is formulated for parenteral administration, intravenous administration, subcutaneous administration, and/or oral administration.

28. The pharmaceutical composition of claim 20, wherein the pharmaceutically acceptable carrier comprises 2-hydroxypropyl-β-cyclodextrin.

29. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition is formulated for mammalian subject suffering a neoplasm.

30. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition is formulated for a mammalian subject suffering or presenting with a history of neoplasm.

31. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition is formulated for a mammalian subject suffering or previously treated into clinical remission for a neoplasm.

32. The pharmaceutical composition of claim 20, wherein the pharmaceutical composition is formulated for a mammalian subject suffering a condition mediated or contributed to by pathogenic neovascularization.

33. Use of a compound of any one of claims 1-18 in the manufacture of a medicament for treating a condition in a subject, wherein the condition comprises one or more of pathogenic cellular proliferation, angiogenesis, cancer, metastatic disease, and/or a pathogenic vascular proliferative disease, and wherein said medicament is to be administered to the subject.

34. The use of claim 33, wherein the pathogenic vascular proliferative disease comprises pathogenic neovascularization associated with a cancer disease or condition.

35. The use of claim 33, wherein the pathogenic vascular proliferative disease comprises an ocular disease.

36. The use of claim 33, wherein the pathogenic vascular proliferative disease is selected from the group consisting of age-related macular degeneration (AMD), diabetic retinopathy, retinopathy of prematurity, sickle cell retinopathy, retinal venous occlusive disease, central retinal vein occlusion (CRVO), branch retinal vein occlusion (BRVO), neovascular macular degeneration or an ocular cancer.

37. The use of claim 33, wherein the pathogenic vascular proliferative disease comprises age-related macular degeneration (AMD).

38. The use of claim 33, wherein the pathogenic vascular proliferative disease comprises wet, exudative age-related macular degeneration.

39. The use of claim 33, wherein the cancer comprises cholangiocarcinoma, triple negative breast cancer, or colorectal cancer.

40. The use of claim 33, wherein the compound is to be administered by parenteral administration, intravenous administration, subcutaneous administration, and/or oral administration.

41. A compound of any one of claims 1-18 for use as a medicament.